1. Barclays Upgrades Phathom on Voquezna Optimism After Stock Pullback
Barclays has upgraded its rating on Phathom Pharmaceuticals, signaling a vote of confidence in the biotech firm following a recent decline in its share price. The move by the major investment bank is directly tied to growing optimism surrounding Phathom's key product, Voquezna. This upgrade represents a significant shi...